POLE and endometrial cancer: Furthermore, the enrichment of TP53 R213* was not present POLE P286R mutant endometrial cancer, it is possible that selection also plays a role as TP53 mutations are more prevalent in colorectal cancers suggesting that there is stronger selective pressure for such mutations which may explain why the enrichment of the TP53 R213* mutation is only present in POLE P286R in colorectal cancer.